tiprankstipranks
Trending News
More News >

Quoin Pharmaceuticals CFO Departure Announcement

Story Highlights
Quoin Pharmaceuticals CFO Departure Announcement

Don’t Miss TipRanks’ Half-Year Sale

Quoin Pharmaceuticals ( (QNRX) ) just unveiled an announcement.

On July 3, 2025, Quoin Pharmaceuticals Ltd. announced that its Chief Financial Officer, Gordon Dunn, will be departing from the company later this year. Dunn will remain in his position until a successor is appointed, and a separation agreement is anticipated to be finalized and filed in the company’s future reports.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Spark’s Take on QNRX Stock

According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.

Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.

To see Spark’s full report on QNRX stock, click here.

More about Quoin Pharmaceuticals

Average Trading Volume: 194,769

Technical Sentiment Signal: Sell

Current Market Cap: $5.22M

Find detailed analytics on QNRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1